Comparative Effects of Valsartan Plus Either Cilnidipine or Hydrochlorothiazide on Home Morning Blood Pressure Surge Evaluated by Information and Communication Technology-based Nocturnal Home Blood Pressure Monitoring
Overview
Affiliations
The authors tested the hypothesis that a valsartan/cilnidipine combination would suppress the home morning blood pressure (BP) surge (HMBPS) more effectively than a valsartan/hydrochlorothiazide combination in patients with morning hypertension, defined as systolic BP (SBP) ≥135 mm Hg or diastolic BP ≥85 mm Hg assessed by a self-measuring information and communication technology-based home BP monitoring device more than three times before either combination's administration. This was an 8-week prospective, multicenter, randomized, open-label clinical trial. The HMBPS, which is a new index, was defined as the mean morning SBP minus the mean nocturnal SBP, both measured on the same day. The authors randomly allocated 129 patients to the valsartan/cilnidipine (63 patients; mean 68.4 years) or valsartan/hydrochlorothiazide (66 patients; mean 67.3 years) combination groups, and the baseline HMBPS values were 17.4 mm Hg vs 16.9 mm Hg, respectively (P = .820). At the end of the treatment period, the changes in nocturnal SBP and morning SBP from baseline were significant in both the valsartan/cilnidipine and valsartan/hydrochlorothiazide groups (P < .001): -5.0 vs -10.0 mm Hg (P = .035) and -10.7 vs -13.6 mm Hg (P = .142), respectively. HMBPS was significantly decreased from baseline in both groups (P < .001), but there was no significant difference between the two groups: 14.4 mm Hg vs 14.0 mm Hg, respectively (P = .892). Valsartan/cilnidipine could not significantly suppress HMBPS compared with valsartan/hydrochlorothiazide. Large-scale randomized controlled studies are needed to assess how reducing HMBPS will affect future cardiovascular outcomes. The information and communication technology-based home BP monitoring device may become an alternative to ambulatory BP monitoring, which has been a gold standard to measure nocturnal BP and the morning BP surge.
Lee E, Wang S, Yip B, Yu E, Leung S, Han J J Pharm Policy Pract. 2025; 18(1):2463435.
PMID: 39968319 PMC: 11834773. DOI: 10.1080/20523211.2025.2463435.
Yan P, Luo Y, Zhang J, Liu H, Chen J, Wang J J Clin Hypertens (Greenwich). 2023; 25(2):137-145.
PMID: 36639984 PMC: 9903188. DOI: 10.1111/jch.14630.
Home Blood Pressure Monitoring: Current Status and New Developments.
Kario K Am J Hypertens. 2021; 34(8):783-794.
PMID: 34431500 PMC: 8385573. DOI: 10.1093/ajh/hpab017.
Clinical studies on pharmacological treatment of hypertension in Japan.
Kario K, Hoshide S, Yamamoto K, Okura A, Rakugi H J Hum Hypertens. 2021; 38(6):486-499.
PMID: 33963269 DOI: 10.1038/s41371-021-00533-4.
Fujiwara T, Hoshide S, Tomitani N, Cheng H, Soenarta A, Turana Y J Clin Hypertens (Greenwich). 2021; 23(3):457-466.
PMID: 33591641 PMC: 8029527. DOI: 10.1111/jch.14218.